HC Wainwright & Co. Reiterates Buy on Onconova Therapeutics, Maintains $11 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Onconova Therapeutics (NASDAQ:ONTX) and maintains an $11 price target.
June 06, 2023 | 10:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst reaffirms Buy rating on Onconova Therapeutics (NASDAQ:ONTX) and keeps $11 price target.
The Buy rating reaffirmation by HC Wainwright & Co. analyst Joseph Pantginis on Onconova Therapeutics (NASDAQ:ONTX) and the maintained $11 price target indicate a positive outlook for the stock. This news is likely to have a positive impact on the stock price in the short term as it shows confidence in the company's potential and may attract more investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100